June 11, 2021 10:08 AM EDTUpdated 10:21 AM

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge

Alex Hoffman

Senior Editor

Kathy Wong

Editor

→ Jason Campagna and Sandip Kapadia were two execs who punched their tickets out of Intercept as things went pear-shaped, and the teetering NASH biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

In­ter­cept re­tools C-suite with a pair of new­com­ers; Charles Ryan moves past Alzheimer's flops with an­oth­er CEO chal­lenge

Senior Editor

Editor

Sign up to read this article for free.

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge